Dark

RNAZ
TransCode Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Jun 17, 2025

6.82USD-6.575%(-0.48)21,597

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 18, 2025 8:26:30 AM EDT

6.90USD+1.173%(+0.08)988

After-hours

Jun 17, 2025 4:45:30 PM EDT

7.03USD0.000%(+7.03)310

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

03:17PM EST TransCode Therapeutics To Participate at H.C. Wainwright GlobeNewswire Inc

Dec 6, 2021

07:10PM EST TransCode Therapeutics To Participate at MedInvest Oncology GlobeNewswire Inc

Nov 15, 2021

04:40PM EST TransCode Therapeutics Q3 EPS $(0.20) Up From $(0.30) YoY Benzinga

04:01PM EST TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results Business Wire

Sep 30, 2021

04:06PM EDT TransCode Therapeutics Appoints Zdravka Medarova As Chief Technology Officer RTTNews

04:01PM EDT TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer Business Wire

Sep 23, 2021

02:48PM EDT Mid-Day Market Update: Dow Jumps Over 500 Points; Eargo Shares Plunge Benzinga

02:47PM EDT Mid-Afternoon Market Update: Crude Oil Surges 1.5%; BlackBerry Shares Spike Higher Benzinga

12:39PM EDT Mid-Day Market Update: Dow Jumps Over 500 Points; Eargo Shares Plunge Benzinga

11:12AM EDT Shares of TransCode Therapeutics, Inc. (RNAZ) are surging over 60% on Thursday morning after the company announced pre-clinical data supporting therapeutic potential of TTX-MC138(MN-anti-miR10b) in metastatic breast cancer. RTTNews

10:18AM EDT Mid-Morning Market Update: Markets Open Higher; Accenture Profit Beats Views Benzinga

07:54AM EDT TransCode Therapeutics Inc. (RNAZ) announced publication in Cancer Nanotechnology of preclinical data supporting therapeutic potential of TTX-MC138(MN-anti-miR10b) in metastatic breast cancer. RTTNews

07:38AM EDT TransCode : Preclinical Data Supports Therapeutic Potential Of TTX-MC138 In Metastatic Breast Cancer; Stock Up RTTNews

07:32AM EDT TransCode Therapeutics Highlights Publication In Cancer Nanotechnology Of Preclinical Data Supporting Therapeutic Potential Of TTX-MC138 In Metastatic Breast Cancer Benzinga

07:30AM EDT TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer Business Wire

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Aug 23, 2021

04:03PM EDT TransCode Therapeutics Ends Q2 With Cash And Cash Equivalents Of ~$80K Benzinga

04:01PM EDT TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results Business Wire

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 5, 2021

08:04AM EDT TransCode Therapeutics Awarded Funding from National Institutes of Health to Support Clinical Evaluation of TTX-MC138 Benzinga

07:30AM EDT TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 Business Wire

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 21, 2021

11:07AM EDT TransCode Therapeutics Shares Up 20%; AIGH Capital Management Earlier Reported In 13G Filing A 9.9% Stake In TransCode Therapeutics Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 13, 2021

04:31PM EDT TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Over-allotment Option Business Wire

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

Jul 9, 2021

10:48AM EDT TransCode Therapeutics Shares Open For Trade At $6; IPO Priced At $4/Share Benzinga

09:24AM EDT TransCode Therapeutics Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $4/Share Benzinga

Jul 8, 2021

06:34PM EDT TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering Business Wire

.dark-mode .d9L96x{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .d9L96x{ color: #333333; background-color: white; border: 2px solid #333333; }RNAZTransCode Therapeutics, Inc. Common Stockstock NASDAQ

RNAZ
TransCode Therapeutics, Inc. Common Stock
stock NASDAQ